Evidence map›Paper›PMID 28550306›Full record

ArticleScientific reports2017

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

D A Casolari, T Nguyen, C M Butcher, D G Iarossi, C N Hahn, S C Bray, P Neufing, W T Parker, J Feng, K Z Y Maung and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cancer discovery · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

D A CasolariCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
T NguyenCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
C M ButcherDepartment of Haematology, SA Pathology and Royal Adelaide Hospital, Adelaide, South Australia, Australia.
D G IarossiCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
C N HahnCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-5105-2554
S C BrayCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
P NeufingBasil Hetzel Institute for Translational Health Research and Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
W T ParkerCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
J FengCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
K Z Y MaungCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
A WeeCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
L VidovicCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
C H KokCancer Theme, SAHMRI, Adelaide, South Australia, Australia.
P G BardyBasil Hetzel Institute for Translational Health Research and Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
S BranfordCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
I D LewisCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
S W LaneQueensland Institute of Medical Research, Brisbane, Queensland, Australia.
H S ScottCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
D M RossDepartment of Haematology, SA Pathology and Royal Adelaide Hospital, Adelaide, South Australia, Australia.ORCID 0000-0001-7171-2935
R J D'AndreaCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia. richard.dandrea@unisa.edu.au.
South Australia Pathology · AUBasil Hetzel Institute · AUQIMR Berghofer Medical Research Institute · AUSouth Australian Health and Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a novel ERBB1/EGFR somatic mutation (p. C329R; c.985 T > C) identified in a patient with JAK2

Indexed as

MutationAmino Acid SequenceCell DifferentiationCell Line, TumorClone CellsErbB ReceptorsErythroblastsErythropoietinGene ExpressionHumansJanus Kinase 2Leukemia, Erythroblastic, AcutePolycythemia VeraPrimary MyelofibrosisProtein MultimerizationSequence AlignmentEGFR protein, humanEPO protein, humanErbB ReceptorsErythropoietinJAK2 protein, humanJanus Kinase 2

Identifiers

PMID28550306
PMCPMC5446393
OpenAlexW2618370121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.